[ad_1]
A new coronavirus vaccine could end the pandemic, but until mass vaccination becomes available, stopping the community spread is vital. The new antiviral drug MK-4482 / EIDD-2801, also known as molnupiravir, which completely suppresses the spread of the coronavirus in just 24 hours, could play a key role in the latter, according to a study from the University’s Institute of Biomedical Sciences. State of Georgia.
“This is the first oral drug that rapidly blocks the spread of SARS-CoV-2, so it could bring a breakthrough,” the researchers explained in a publication in the journal Nature Microbiology. The antiviral drug was developed at Emory University in Atlanta by Drug Innovation Ventures at Emory, a pharmaceutical innovation company (DRIVE), originally designed to treat the flu.
The drug has not yet been commercialized, as currently only clinical trials II / III are available. phase. It is reported to be tested in three different doses in SARS-CoV-2 infected patients for five days at two doses per day.
If the researchers’ expectations are met, the drug, by rapidly blocking the spread of the virus, will not only prevent the infection from becoming a severe Covid-19 disease, but will shorten the infectious phase and quickly slow down the development of local epidemics. .
[ad_2]
